(firstQuint)Safety and PK Trial With Injectable ZX003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia.

 Approximately 75 male and female patients with schizophrenia or schizoaffective disorder on antipsychotic maintenance medication will be enrolled into the study.

 There will be 4 planned cohorts of 14 patients per cohort.

 In Cohorts 1-3, patients' planned participation in the study is for a total of approximately 22 weeks, including a Screening period of up to 35 days, and a study treatment period of 120 days (including follow-up).

 In Cohort 4 planned participation in the study is for a total of approximately 18 weeks including a Screening period of up to 35 days and a study treatment of 92 days (including follow-up).

.

 Safety and PK Trial With Injectable ZX003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia@highlight

This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.

